Profitelligence Profitelligence · Filing Ledger Open GILD research →

Form 8-K · Current Report · Filed 2024-07-17

Gilead Sciences Announces Departure of Chief Medical Officer Merdad Parsey

Gilead Sciences, Inc. announced on July 17, 2024, that Chief Medical Officer Merdad V. Parsey, M.D., Ph.D., will leave the company early next year. Dr. Parsey will continue in his role until Q1 2025 while the company identifies a successor. During his tenure, Dr. Parsey led the growth of Gilead's global clinical development and medical affairs organizations, contributing significantly to the company's pipeline advancements in virology, oncology, and inflammation.

Filer
Gilead Sciences Inc. GILD · NASDAQ
Filed
Accession
0001104659-24-080355
CIK
0000882095
Signal
High impactHealthcare

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

CFO Resignation
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$71.64

Next session

+2.6%

Since filing

+81.8%

Latest close

$130.21

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from GILD reporting the same item, with the next session's move:

Exhibits (1)

About Gilead Sciences Inc.

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another GILD filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts